바이오테크 보도자료
-
- Rigaku Launches Fourth Generation Handheld 1064 nm Raman Analyzer for Chemical Threat Analysis at IAFC HAZMAT 2025
- Rigaku Analytical Devices, a division under Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; President and CEO: Jun Kawakami), announces the launch of its fourth generation 1064 nm Raman analyzers...
- 13:35
-
- Merck Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025
- Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of detailed results from Cohort B of the global Phase 2 WILLOW study (NCT0516...
- 08:53
-
- FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025
- Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Foo...
- 08:43
-
- Novotech Showcased in Global Biotech Series for Innovation in Hepatitis B Research
- Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company, is featured in The Next Frontier, a global branded series presented by the Biotechnology Inn...
- 06월 11일 15:00
-
- Medisca Secures Settlement With FlackTek, Reinforcing Patent Strength of MAZ® Mixer
- Medisca and FlackTek have reached a settlement to resolve their patent dispute relating to the Medisca MAZ® mixer and related mixing technologies set forth in Medisca U.S. patent numbers 10,420,705, 10,765,6...
- 06월 11일 09:43
-
- Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults
- Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Foo...
- 06월 11일 09:02
-
- Yokogawa Announces Release of Next-Generation of the CENTUM VP Integrated Production Control System
- Yokogawa Electric Corporation (TOKYO: 6841) announces the unveiling of the next-generation Release 7 concept and the launch of Release 7.01 of the CENTUM™ VP integrated production control system, a core prod...
- 06월 10일 11:40
-
- Samsung Bioepis Enters into a Strategic Partnership with NIPRO for Commercialization of Multiple Biosimilars in Japan
- Samsung Bioepis Co., Ltd. (“Samsung Bioepis”) announced today that the company has entered into a license, development and commercialization agreement with NIPRO Corporation (“NIPRO”) for multiple biosimilar...
- 06월 09일 11:44
-
- RAD 2025: Long-Term Data on Nemluvio® (nemolizumab) Demonstrate its Favorable Safety Profile and Sustained and Increased Improvements in Itch and Skin Lesions in Patients With Atopic Dermatitis up to Two Years
- Galderma (SIX: GALD) today announced two-year data from a new interim analysis of a long-term extension study investigating the safety and efficacy of Nemluvio in moderate-to-severe atopic dermatitis. The da...
- 06월 08일 11:35
-
- Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform
- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315) today announced that the key technology of its independently developed RenMab™ fully human antibody mouse platform has been granted an...
- 06월 08일 11:20
-
- ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis
- ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application...
- 06월 05일 17:20
전시회
